Okeiro

The Digital Twin accelerates access to innovative therapies and optimizes existing treatments for clinical trials.

The page describes how iBox, a validated predictive algorithm, estimates the individual risk of losing a kidney graft up to 10 years after assessment.

The RWE system transforms healthcare data management by enabling the use of patient data to improve clinical outcomes.

Okeiro demonstrates how its algorithms predict and adapt treatments for transplant patients and those with chronic diseases.

Okeiro’s algorithms predict complications and adjust treatments for transplant patients and those with chronic illnesses.

Okeiro secures €10 million in funding to expand its AI-driven platform, targeting advancements in transplantation. The company leverages artificial intelligence to optimize organ allocation and improve patient outcomes. Okeiro operates within the life sciences sector, focusing on critical healthcare innovations.

Apr 2025biotech-finances.comNews article

Okeiros secures Series A funding to address critical shortages in organ transplants, particularly for kidney patients. The company focuses on reducing risks and improving outcomes for transplant recipients, where one in six currently loses their graft. France alone has nearly 20,000 patients awaiting kidney transplants, highlighting the growing demand for solutions in chronic disease care.

Apr 2025redriverwest.substack.comNews article

Okeiro, a Paris-based precision medicine company, secures €10 million in funding to advance transplantation and chronic disease treatments. The company, previously named Predict4Health, focuses on developing tailored medical solutions for complex health conditions.

Apr 2025FinSMEsNews article

Okeiro (formerly Predict4Health) has raised €10 million in funding to expand its AI-powered clinical decision support platform. The platform targets precision medicine applications in transplantation and chronic disease management. Investors Alven, Forepont Capital Partners, and Red River West are leading the round.

Apr 2025MedPath TrialNews article